Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

India’s COVID-vaccine woes — by the numbers

How an explosion of coronavirus cases in India is putting global vaccine supplies at risk.
  1. T. V. Padma
    View author publications

    You can also search for this author in PubMed  Google Scholar

India, one of the world’s biggest suppliers of vaccines, is facing a COVID-19 vaccine crunch, partly due to an explosion of cases linked to new variants. This spells trouble for many countries relying on Indian-made vaccines supplied through the COVAX initiative for equitable access to vaccines, led by bodies including the World Health Organization.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 592, 500-501 (2021)

doi: https://doi.org/10.1038/d41586-021-00996-y

Updates & Corrections

  • Correction 16 April 2021: An earlier version of this story misrepresented the World Health Organization’s involvement in the COVAX initiative: it is a co-leader, not the owner. The earlier version also misspelt Shahid Jameel’s name.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links